Brief: SciSparc Gets FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
23/09/2024 14:42
Sept 23 (Reuters) - Scisparc Ltd SPRC.O :
* SCISPARC RECEIVES FDA APPROVAL TO INITIATE PHASE IIB
CLINICAL
TRIAL FOR TOURETTE SYNDROME TREATMENT
* SCISPARC LTD - FDA CONFIRMS SCISPARC'S STUDY MAY PROCEED
Source text for Eikon: ID:nGNX4PwrTf
Further company coverage: SPRC.O
((Reuters.Briefs@thomsonreuters.com;))